Cencora, Inc.
COR · Healthcare
$330.97
Caricamento grafico…
Notizie
Ultime notizie su questo titolo
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora reported Q3 fiscal 2026 adjusted EPS of $4.48, beating consensus estimates by 2.5%, with 12% year-over-year earnings growth. Revenue rose 5.1% to $84.76 billion but slightly missed expectations. The company raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 and increased operating income growth outlook to 13-14%. However, post-earnings estimates have trended downward, and the stock received a Zacks Rank #3 (Hold) rating.
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora (COR) raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 following stronger-than-expected third-quarter results. The company's U.S. segment profit grew 15.9% driven by specialty sales and GLP-1 demand, while international operating income rose 20.8%. However, headwinds from lower-margin GLP-1 products, manufacturer price reductions, and higher financing costs tempered upside. The stock maintains a Zacks Rank #3 (Hold) rating.
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generics business continues to be a steady profit contributor, with fiscal 2026 volume growth exceeding long-term planning assumptions of 2-3%. The company expects fiscal 2027 to benefit from new generic launches, brand-to-generic conversions, and stable Red Oak program dynamics, supporting projected Pharma segment profit growth of 8-11%. Peers McKesson and Cencora also show strength in their pharmaceutical distribution and generics portfolios.